email article
Developing COVID-19 during a high-risk pregnancy is a bad combination for mother and child, but having HIV infection on top of that doesn t appear to make it any worse, a study in South Africa indicated.
Of 100 women diagnosed with COVID-19 while receiving care from the high-risk obstetric care service at Tygerberg Hospital in Cape Town, South Africa, there were eight deaths: six among the 72 women (8%) with COVID-19, and two among the 28 women (7%) co-infected with HIV, said Liesl De Waard, MBChB, of Stellenbosch University in suburban Cape Town.
Of those women who died during the study conducted during the height of the COVID-19 pandemic only two of the babies they were carrying survived, de Waard said in her oral presentation at the virtual Conference on Retroviruses and Opportunistic Infections (CROI).
email article
Dolutegravir (Tivicay)-based antiretroviral therapy in children with HIV infection was superior to efavirenz-based standard of care in the first-line setting in a prospective trial, researchers reported.
In her presentation at the virtual Conference on Retroviruses and Opportunistic Infections, Anna Turkova, MD, of University College London, added that in the second-line setting, it appears dolutegravir-based treatment is at least non-inferior to current treatment regimens.
Reporting for the ODYSSEY/PENTA-20 Trial team, she said the international, multicenter, randomized 96-week trials had 47 virologic failure events (14%) among children on dolutegravir compared with 75 (22%) among children on efavirenz, a difference that for this primary endpoint of the trial reached statistical significance (
HIV PrEP: Annual Implant Moves Closer to the Clinic medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
email article
South Africans living with HIV who paid to have antiretroviral therapy (ART) delivered had higher rates of viral suppression than those who got their medication at a clinic, a researcher said.
In a randomized trial of 162 people living with HIV, 88% of those randomized to home delivery of ART experienced viral suppression (defined as viral loads less than 100 copies/ml) versus 74% of those randomized to clinic visits (RR 1.21, 95% CI 1.02-1.42), reported Ruanne Barnabas, MBChB, DPhil, of the University of Washington in Seattle.
Moreover, these differences in viral suppression were more pronounced among South African men (64% in clinic group vs 84% in home group, RR 1.31, 95% CI 1.01-1.71), she said in a late-breaking presentation at the virtual Conference on Retroviruses and Opportunistic Infections (CROI).